{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:38:48Z","timestamp":1793709528351,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.06.023","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:00:08Z","timestamp":1782889208000},"page":"1946-1953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating elevated lipoprotein(a) clinical care impact in an academic health center"],"prefix":"10.1016","volume":"20","author":[{"given":"Aida","family":"Roman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-8219","authenticated-orcid":false,"given":"Shane J.","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3287-6002","authenticated-orcid":false,"given":"John G.","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jacl.2026.06.023_bib1","first-page":"1","article-title":"Deaths: leading causes for 2020","volume":"72","author":"Curtin","year":"2023","journal-title":"Natl Vital Stat Rep"},{"issue":"8","key":"10.1016\/j.jacl.2026.06.023_bib2","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.06.023_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.jacl.2026.06.023_bib4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.06.023_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacl.2026.06.023_bib6","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.jacl.2026.06.023_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jacl.2026.06.023_bib8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2026.06.023_bib9","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacl.2022.08.007","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national lipid association","volume":"16","author":"Wilson","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.06.023_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.06.023_bib11","first-page":"1129","article-title":"2021 canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"24","key":"10.1016\/j.jacl.2026.06.023_bib12","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.06.023_bib13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"18","key":"10.1016\/j.jacl.2026.06.023_bib14","doi-asserted-by":"crossref","first-page":"e031255","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein\u00a0testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jacl.2026.06.023_bib15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jacl.2023.09.016","article-title":"Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease","volume":"17","author":"Panza","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.06.023_bib16","doi-asserted-by":"crossref","first-page":"100478","DOI":"10.1016\/j.ajpc.2023.100478","article-title":"Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes","volume":"14","author":"Kelsey","year":"2023","journal-title":"Am J Prev Cardiol"},{"issue":"33","key":"10.1016\/j.jacl.2026.06.023_bib17","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2026.06.023_bib18","doi-asserted-by":"crossref","first-page":"e033562","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the multi-ethnic study of atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.06.023_bib19","first-page":"04","article-title":"Aspirin use for primary prevention among US adults with and without elevated lipoprotein(a)","volume":"18","author":"Razavi","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.06.023_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2026.06.023_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.jacl.2026.06.023_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:19:28Z","timestamp":1793708368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1933287426004204"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.06.023","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating elevated lipoprotein(a) clinical care impact in an academic health center","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}